Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Ratko Djukanović, Paul Brinkman, Johan Kolmert, Cristina Gomez, James Schofield, Joost Brandsma, Andy Shapanis, Paul J S Skipp, Anthony Postle, Craig Wheelock, Sven-Erik Dahlen, Peter J Sterk, Thomas Brown, David J Jackson, Adel Mansur, Ian Pavord, Mitesh Patel, Christopher Brightling, Salman Siddiqui, Peter Bradding, Ian Sabroe, Dinesh Saralaya, Livingstone Chishimba, Joanna Porter, Douglas Robinson, Stephen Fowler, Peter H Howarth, Louisa Little, Thomas Oliver, Kayleigh Hill, Louise Stanton, Alexander Allen, Deborah Ellis, Gareth Griffiths, Tim Harrison, Ayobami Akenroye, Jessica Lasky-Su, Liam Heaney, Rekha Chaudhuri, Ramesh Kurukulaaratchy
BACKGROUND: The anti-IgE monoclonal, omalizumab, is widely used for severe asthma. This study aimed to identify biomarkers that predict clinical improvement during one year of omalizumab treatment. METHODS: 1-year, open-label, S tudy o f M echanisms of action of O malizumab in S evere A sthma ( SoMOSA ) involving 216 severe (GINA step 4/5) uncontrolled atopic asthmatics (≥2 severe exacerbations in previous year) on high-dose inhaled corticosteroids, long-acting β-agonists, ± mOCS...
April 18, 2024: American Journal of Respiratory and Critical Care Medicine
#2
JOURNAL ARTICLE
Yanan Zheng, Lubna Abuqayyas, Angelica Quartino, Ye Guan, Yuying Gao, Lu Liu, Åsa Hellqvist, Gene Colice, Alexander MacDonald
Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin. This analysis assessed the suitability of a fixed-dose regimen of tezepelumab 210 mg every 4 weeks (Q4W) in adults and adolescents with severe, uncontrolled asthma. A population pharmacokinetic model was developed using data from 1368 patients with asthma or healthy participants enrolled in 8 clinical studies (phases 1-3). Tezepelumab exposure-efficacy relationships were analyzed in the phase 3 NAVIGATOR study (NCT03347279), using asthma exacerbation rates over 52 weeks and changes in pre-bronchodilator forced expiratory volume in 1 s at week 52...
April 17, 2024: Journal of Clinical Pharmacology
#3
JOURNAL ARTICLE
Flory L Nkoy, Bryan L Stone, Yue Zhang, Gang Luo
Inhaled corticosteroid (ICS) is a mainstay treatment for controlling asthma and preventing exacerbations in patients with persistent asthma. Many types of ICS drugs are used, either alone or in combination with other controller medications. Despite the widespread use of ICSs, asthma control remains suboptimal in many people with asthma. Suboptimal control leads to recurrent exacerbations, causes frequent ER visits and inpatient stays, and is due to multiple factors. One such factor is the inappropriate ICS choice for the patient...
April 17, 2024: JMIR Medical Informatics
#4
JOURNAL ARTICLE
Melissa A Kovach, Ulrika Käck, Karlhans F Che, Bettina Brundin, Jon R Konradsen, Anders Lindén
BACKGROUND: Interleukin (IL)-26 is produced by T helper type 17 (Type 17) cells and exerts immunomodulatory plus antimicrobial effects. Previous studies show that local IL-26 concentrations in the airways are higher in patients with uncontrolled than in those with controlled asthma, and that this intriguing cytokine bears biomarker potential. Here, we determined how systemic IL-26 relates to allergen sensitization, asthma severity, and to IL-17 A in children. METHODS: Serum samples were obtained from children with (n = 60) and without (n = 17) sensitization to dog allergen, and IL-26 and IL-17 A protein concentrations were measured using ELISA...
April 15, 2024: Respiratory Research
#5
JOURNAL ARTICLE
Aram Karkar, Sana Khan, Rebecca O'Leary, Albina Tyker, Michael Unger
The field of pulmonology saw significant advances in 2023. The publications highlighted in this article address advances and changes in practice related to asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, pleural disorders, and sleep-disordered breathing. One article reviews data examining the efficacy of vaccination against respiratory syncytial virus, a respiratory viral illness that has had devastating effects globally. Four studies evaluate the role of various therapies in COPD, including dupilumab, ensifentrine, pulmonary rehabilitation programs, and lung volume reduction versus endobronchial valves...
April 16, 2024: Annals of Internal Medicine
#6
JOURNAL ARTICLE
Lee Hatter, Mark Holliday, Allie Eathorne, Pepa Bruce, Ian D Pavord, Helen K Reddel, Robert J Hancox, Alberto Papi, Mark Weatherall, Richard Beasley
INTRODUCTION: The use of pressurised metered-dose inhalers (pMDIs) and asthma exacerbations necessitating healthcare reviews contribute substantially to the global carbon footprint of healthcare. It is possible that a reduction in carbon footprint could be achieved by switching patients with mild asthma from salbutamol pMDI reliever therapy to inhaled corticosteroid-formoterol dry powder inhaler (DPI) reliever therapy, as recommended by the Global Initiative for Asthma (GINA). METHODS: This post hoc analysis included all 668 adult participants in the Novel START trial, who were randomised 1:1:1 to treatment with: as-needed budesonide-formoterol DPI, as-needed salbutamol pMDI, or maintenance budesonide DPI plus as-needed salbutamol pMDI...
April 12, 2024: European Respiratory Journal
#7
JOURNAL ARTICLE
Marianne Baastrup Søndergaard, Frederik Roager Madsen, Asger Sverrild, Celeste Porsbjerg
In the last 30 years, the treatment of obstructive lung diseases, such as asthma and COPD, has seen significant advancements. Introduction of inhaled corticosteroids (ICS) and, more recently, biological treatments has revolutionized care. Biological treatments are very successful in severe asthma and are expected to be approved for COPD soon. Systematic assessment and multidimensional treatment approaches are crucial in both conditions. Future care may involve specialized centres for severe obstructive lung diseases, focusing on personalized approaches and monitoring, as argued in this review...
April 1, 2024: Ugeskrift for Laeger
#8
JOURNAL ARTICLE
Yafeng Liang, Sijia Shen, Xiaoxiao Ye, Weixi Zhang, Xixi Lin
Obese asthma is a unique asthma phenotype that decreases sensitivity to inhaled corticosteroids, and currently lacks efficient therapeutic medication. Celastrol, a powerful bioactive substance obtained naturally from the roots of Tripterygium wilfordii, has been reported to possess the potential effect of weight loss in obese individuals. However, its role in the treatment of obese asthma is not fully elucidated. In the present study, diet induced obesity (DIO) mice were used with or without ovalbumin (OVA) sensitization, the therapeutic effects of celastrol on airway hyperresponsiveness (AHR) and airway inflammation were examined...
April 9, 2024: European Journal of Pharmacology
#9
JOURNAL ARTICLE
Xiaotian Ju, Akimichi Nagashima, Anna Dvorkin-Gheva, Jennifer Wattie, Karen Howie, Christiane Whetstone, Maral Ranjbar, Ruth Cusack, Reina Ditta, Guillaume Paré, Imran Satia, Paul M O'Byrne, Gail M Gauvreau, Roma Sehmi
RATIONALE: In asthma, sputum group 2 innate lymphoid cells (ILC2) are activated within 7h after allergen challenge. Neuroimmune interactions mediate rapid host responses at mucosal interfaces. In murine models of asthma, lung ILC2 co-localize to sensory neuronal termini expressing the neuropeptide, neuromedin U (NMU) and NMU stimulates type 2 cytokines secretion by ILC2 with additive effects to alarmins, in vitro . OBJECTIVES: Investigate effect of NMU/NMUR1 axis on early activation of ILC2 in asthma...
April 10, 2024: American Journal of Respiratory and Critical Care Medicine
#10
JOURNAL ARTICLE
Melissa H Roberts, Mei Sheng Duh, Kieran J Rothnie, Shiyuan Zhang, Alexandrosz Czira, David Slade, Wendy Y Cheng, Philippe Thompson-Leduc, Alexandra Greatsinger, Adina Zhang, Douglas Mapel
INTRODUCTION: Definitions of moderate asthma exacerbation have been inconsistent, making their economic burden difficult to assess. An algorithm to accurately identify moderate exacerbations from claims data is needed. METHODS: A retrospective cohort study of Reliant Medical Group patients aged ≥18 years, with ≥1 prescription claim for inhaled corticosteroid/long-acting β2 -agonist, and ≥1 medical claim with a diagnosis code for asthma was conducted...
April 7, 2024: Respiratory Medicine
#11
JOURNAL ARTICLE
Mei Sheng Duh, Melissa H Roberts, Kieran J Rothnie, Wendy Y Cheng, Philippe Thompson-Leduc, Shiyuan Zhang, Alexandrosz Czira, David Slade, Alexandra Greatsinger, Adina Zhang, Douglas Mapel
INTRODUCTION: Despite adherence to inhaled corticosteroid/long-acting β2 -agonist (ICS/LABA) therapy, many patients with asthma experience moderate exacerbations. Data on the impact of moderate exacerbations on the healthcare system are limited. This study assessed the frequency and economic burden of moderate exacerbations in patients receiving ICS/LABA. METHODS: Retrospective, longitudinal study analyzed data from Optum's de-identified Clinformatics® Data Mart Database recorded between October 1, 2015, and December 31, 2019...
April 7, 2024: Respiratory Medicine
#12
JOURNAL ARTICLE
Christopher Alexander Hinze, Rainer Ehmann, Margret Jandl, Katrin Milger, Olaf Schmidt, Christian Schulz, Dirk Skowasch, Tobias Welte, Roland Buhl, Eckard Hamelmann, Marco Idzko, Christian Taube, Stephanie Korn, Hendrik Suhling
After the GINA update in 2019, the proportion of SMART therapy increased with evidence for better disease control in SMART patients compared to SABA alone https://bit.ly/3SSPX1C.
March 2024: ERJ Open Research
#13
JOURNAL ARTICLE
Tasmin Barry, Mark Holliday, Jenny Sparks, Rowan Biggs, Atalie Colman, Rebekah Lamb, Karen Oldfield, Nick Shortt, Kyley Kerse, John Martindale, Allie Eathorne, Michaela Walton, Bianca Black, Matire Harwood, Pepa Bruce, Ruth Semprini, Andrew Bush, Louise Fleming, Catherine A Byrnes, David McNamara, Lee Hatter, Stuart R Dalziel, Mark Weatherall, Richard Beasley
BACKGROUND: Asthma is the most common chronic childhood respiratory condition globally. Inhaled corticosteroid (ICS)-formoterol reliever-based regimens reduce the risk of asthma exacerbations compared with conventional short-acting β2 -agonist (SABA) reliever-based regimens in adults and adolescents. The current limited evidence for anti-inflammatory reliever therapy in children means it is unknown whether these findings are also applicable to children. High-quality randomised controlled trials (RCTs) are needed...
March 2024: ERJ Open Research
#14
JOURNAL ARTICLE
Connie L Yang, Zofia Zysman-Colman, Estelle Chétrit, Anne Hicks, Joseph Reisman, Amy Glicksman
This practice point summarizes recommendations from the Canadian Thoracic Society's 2021 "Guideline update: Diagnosis and management of asthma in preschoolers, children, and adults." New recommendations include: a decrease in the frequency of daytime symptoms and reliever use to ≤2 per week in the asthma control criteria; assessing for risk of asthma exacerbation; not using as-needed short-acting beta-agonists alone in patients at higher risk for exacerbation; and the option of as-needed budesonide/formoterol (bud/form) in those ≥12 years old if they are unable to take daily inhaled corticosteroids despite extensive asthma education and support...
May 2024: Paediatrics & Child Health
#15
JOURNAL ARTICLE
Manuela Latorre, Angela Rizzi, Pierluigi Paggiaro, Ilaria Baiardini, Diego Bagnasco, Stefano DelGiacco, Carlo Lombardi, Vincenzo Patella, Eleonora Nucera, Roberta Parente, Giovanni Paoletti, Laura Pini, Erminia Ridolo, Gianenrico Senna, Francesco Blasi, Giorgio Walter Canonica, Arianna Aruanno, Carmen Ballacchino, Marco Bonavia, Cecilia Calabrese, Marco Caminati, Monica Carbonara, Cristina Cardini, Cristiano Caruso, Luciano Cattani, Maria Angiola Crivellaro, Alessandra Diana, Eugenia Durante, Elisabetta Favero, Maria Pia Foschino Barbaro, Sandra Frateiacci, Gabriella Guarnieri, Alessia Lofaro, Francesca Losa, Nadia Magarò, Francesco Menzella, Luisa Ricciardi, Giulia Scioscia, Elisa Testino, Francesca Torracca
OBJECTIVE: Patients' perceptions of asthma symptoms, and attitudes regarding diagnosis and management, can affect their ability to reach good asthma control. The aim of the study was to explore patients' perceptions of asthma management, with focus on treatment with oral corticosteroids (OCS). METHODS: A DOXAPHARMA survey was conducted. A questionnaire with 46 multiple choice questions was completed by 50 patients with severe uncontrolled asthma, and 258 with mild-moderate controlled or partly controlled asthma...
April 5, 2024: Journal of Asthma
#16
JOURNAL ARTICLE
Kefang Lai, Dejun Sun, Ranran Dai, Ronnie Samoro, Hae-Sim Park, Annika Åstrand, David Cohen, Maria Jison, Vivian H Shih, Viktoria Werkström, Yuhui Yao, Yajuan Zhang, Wenying Zheng, Nanshan Zhong, Albay Albert, Bo Jianping, Chen Bi, Chen Lijun, Chen Mei, Chen Min, Chen Ping, Chen Zhimin, Chian Chih-Feng, Cho You Sook, Fu Xiuhua, Gao Xiwen, Gu Wei, Han Wei, Han Zhihai, Hu Xi Wei, Huang Kewu, Huang Mao, Isidro Marie Grace Dawn, Jeong Inbeom, Jiang Luning, Jiang Mingyan, Jiang Shanping, Jin Meiling, Kang Jian, Kim Jin Woo, Kim Sang-Ha, Kuang Jiulong, Kuo Ping-Hung, Li Jie, Li Manxiang, Li Minjing, Li Ruoran, Li Wen, Li Xianhua, Li Yanming, Lim Seong Yong, Liu Chuanhe, Liu Chuntao, Liu Jing, Liu Xiaoxia, Lu Huiyu, Luo Zhuang, Ma Shengxi, Mao Liangping, Min Kyung Hoon, Mu Lin, Park Choon-Sik, Park Hae Sim, Park Hye-Kyung, Park Jung-Won, Perng Diahn-Warng, Samoro Ronnie, Shi Guochao, Sun Debin, Sun Dejun, Wang Chun-Hua, Wang Guangfa, Wang Limin, Wang Xuefen, Wang Yan, Wei Liping, Wu Haihong, Xiao Yi, Xiao Zuke, Xie Canmao, Xu Jin-Fu, Xu Xingxiang, Xu Xiyuan, Yan Jianping, Yang Hongzhong, Yoon Ho Joo, Yu Wencheng, Zhang Jin, Zhang Longju, Zhang Min, Zhang Wei, Zhao Jianping, Zhao Ziwen, Zhu Xiaoli, Zhu Yingqun
BACKGROUND: Benralizumab is indicated as add-on therapy in patients with uncontrolled, severe eosinophilic asthma; it has not yet been evaluated in a large Asian population with asthma in a clinical trial. OBJECTIVE: To evaluate the efficacy and safety of benralizumab in patients with severe asthma in Asia. METHODS: MIRACLE (NCT03186209) was a randomized, Phase 3 study in China, South Korea, and the Philippines. Patients aged 12-75 years with severe asthma receiving medium-to-high-dose inhaled corticosteroid/long-acting β2 -agonists, stratified (2:1) by baseline blood eosinophil count (bEOS) (≥300/μL; <300/μL), were randomized (1:1) to benralizumab 30 mg or placebo...
April 1, 2024: Respiratory Medicine
#17
REVIEW
Leslie Hendeles, Miles Weinberger
No abstract text is available yet for this article.
March 29, 2024: Paediatric Respiratory Reviews
#18
JOURNAL ARTICLE
Danny Darmawan, Iris Rengganis, Cleopas Martin Rumende, Hamzah Shatri, Soekamto Koesnoe, Yogi Umbarawan, Rudi Putranto, Sally Aman Nasution
BACKGROUND: Asthma is a disease characterized by chronic airway inflammation, however one-third of asthmatic cases did not respond adequately. Inhaled magnesium has been proposed as a treatment for unresponsive asthma cases. However, its role remains controversial. This review evaluates the effectiveness and safety of nebulized magnesium compared to standard therapy (Beta Agonist, Anticholinergic, Corticosteroid) in adults with acute asthma attacks. METHODS: The protocol has been registered in PROSPERO...
January 2024: Acta Medica Indonesiana
#19
JOURNAL ARTICLE
Arzu Yorgancıoğlu, Alvaro A Cruz, Gabriel Garcia, Kim L Lavoie, Nicolas Roche, Manish Verma, Anurita Majumdar, Swarnendu Chatterjee
INTRODUCTION/BACKGROUND: Mild asthma treatment recommendations include intermittent inhaled corticosteroid (ICS)/formoterol dosing or regular ICS dosing with short-acting β2 -agonist reliever. Due to the heterogeneity of asthma, identification of traits associated with improved outcomes to specific treatments would be clinically beneficial. AIMS/OBJECTIVES: To assess the impact of patient traits on treatment outcomes of regular ICS dosing compared with intermittent ICS/formoterol dosing, a systematic literature review (SLR) and network meta-analysis (NMA) was conducted...
March 30, 2024: Respiratory Medicine
#20
RANDOMIZED CONTROLLED TRIAL
Matthew B Stanbrook
Jackson DJ, Heaney LG, Humbert M, et al; SHAMAL Investigators. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Lancet. 2024;403:271-281. 38071986.
April 2024: Annals of Internal Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
